Solventum Corporation (SOLV)
Automate Your Wheel Strategy on SOLV
With Tiblio's Option Bot, you can configure your own wheel strategy including SOLV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SOLV
- Rev/Share 48.2042
- Book/Share 28.6059
- PB 2.8522
- Debt/Equity 1.0303
- CurrentRatio 1.5
- ROIC 0.1814
- MktCap 14151344669.0
- FreeCF/Share 0.2869
- PFCF 283.0269
- PE 9.3315
- Debt/Assets 0.3676
- DivYield 0
- ROE 0.4104
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SOLV | BTIG Research | Neutral | Buy | -- | $100 | Dec. 2, 2025 |
| Initiation | SOLV | UBS | -- | Neutral | -- | $77 | Oct. 1, 2025 |
| Initiation | SOLV | Jefferies | -- | Hold | -- | $80 | Sept. 11, 2025 |
| Upgrade | SOLV | Morgan Stanley | Equal Weight | Overweight | -- | $103 | July 15, 2025 |
| Upgrade | SOLV | Argus | Hold | Buy | -- | $90 | July 1, 2025 |
| Initiation | SOLV | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | June 6, 2025 |
| Upgrade | SOLV | Piper Sandler | Neutral | Overweight | -- | $87 | May 19, 2025 |
| Initiation | SOLV | Mizuho | -- | Neutral | -- | $70 | Dec. 4, 2024 |
| Initiation | SOLV | Stifel | -- | Buy | -- | $82 | Oct. 8, 2024 |
| Initiation | SOLV | Piper Sandler | -- | Neutral | -- | $71 | Oct. 7, 2024 |
News
Solventum Corporation: Cheap, With Caveats
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price.
Read More
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Read More
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
Read More
Solventum (SOLV) Soars 8.8%: Is Further Upside Left in the Stock?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy
Published: March 21, 2025 by: Benzinga
Sentiment: Positive
On Thursday, Solventum SOLV hosted its 2025 Investor Day, during which it outlined its strategic priorities, its business segments, and its long-range plan (LRP) to drive growth and value creation.
Read More
Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Provides 2028 Targets for Revenue Growth, Margin Expansion, and Free Cash Flow ST. PAUL, Minn.
Read More
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Read More
Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Solventum Corporation (NYSE:SOLV ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations and External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler & Co. Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Vikramjeet Chopra - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company, Inc. Operator Good afternoon. My name is Ellie, and I will be your conference call operator today.
Read More
Solventum forecasts annual profit above estimates on strong surgical product sales
Published: February 27, 2025 by: Reuters
Sentiment: Positive
3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Read More
Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports
Published: February 26, 2025 by: Reuters
Sentiment: Positive
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Read More
Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion
Published: February 25, 2025 by: Reuters
Sentiment: Positive
Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.
Read More
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics.
Read More
About Solventum Corporation (SOLV)
- IPO Date 2024-04-01
- Website https://www.solventum.com
- Industry Medical - Care Facilities
- CEO Bryan C. Hanson
- Employees 22000